Highlander Capital Management’s Sage Therapeutics SAGE Stock Holding History

Highlander Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-500	Closed	-$37K	–	628
2021 Q1	$37K	Buy	+500	New	+$41K	0.02%	322
2020 Q1	–	Sell	-500	Closed	-$36K	–	651
2019 Q4	$36K	Buy	+500	New	+$61.5K	0.02%	338
2019 Q3	–	Sell	-300	Closed	-$55K	–	682
2019 Q2	$55K	Hold	300	–	–	0.03%	301
2019 Q1	$48K	Buy	+300	New	+$43.4K	0.03%	328
2017 Q3	–	Sell	-1,000	Closed	-$80K	–	763
2017 Q2	$80K	Hold	1,000	–	–	0.06%	277
2017 Q1	$71K	Hold	1,000	–	–	0.06%	291
2016 Q4	$51K	Hold	1,000	–	–	0.04%	332
2016 Q3	$46K	Buy	+1,000	New	+$40.7K	0.04%	369

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Highlander Capital Management's SAGE Position: Q2 2021 in Review

Highlander Capital Management sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 500 shares — an estimated $37K sold.

Highlander Capital Management first reported a position in SAGE in Q3 2016 and held it in 8 quarters. The position peaked at $80K in Q2 2017. 256 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

Highlander Capital Management reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
Highlander Capital Management sold 500 Sage Therapeutics shares in Q2 2021, an estimated $37K.
Highlander Capital Management first reported a position in Sage Therapeutics in Q3 2016 and held it in 8 quarters.
Highlander Capital Management's Sage Therapeutics position peaked at $80K in Q2 2017.
256 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Highlander Capital Management's 13F filing for Q2 2021, filed 10 Aug 2021.